Lack of Immunotoxicity After Regional Intravenous (RI) Delivery of rAAV to Nonhuman Primate Skeletal Muscle
Open Access
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (1) , 151-160
- https://doi.org/10.1038/mt.2009.251
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyProceedings of the National Academy of Sciences, 2009
- AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cellsBlood, 2009
- Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteinsAnnals of Neurology, 2009
- Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate MuscleJournal of Virology, 2008
- Impact of Preexisting Vector Immunity on the Efficacy of Adeno-Associated Virus-Based HIV-1 Gag VaccinesHuman Gene Therapy, 2008
- Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus VectorsJournal of Virology, 2008
- Major role of local immune responses in antibody formation to factor IX in AAV gene transferGene Therapy, 2005
- Autoimmune anemia in macaques following erythropoietin gene therapyBlood, 2004
- Erythropoietin gene therapy leads to autoimmune anemia in macaquesBlood, 2004
- Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene TherapyHuman Gene Therapy, 2002